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Abstract 
Chronic skin ulcerations are a common complication of diabetes mellitus, affecting up 
to one in four diabetic individuals. Despite the prevalence of these wounds, current 
pharmacologic options for treating them remain limited. Growth factor-based 
therapies have displayed a mixed ability to drive successful healing, which may be 
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due to non-optimal delivery strategies. Here we describe a method for coating 
commercially available nylon dressings using the Layer-by-Layer (LbL) process to 
enable both sustained release and independent control over the release kinetics of 
VEGF and PDGF-BB. We show that the use of strategically spaced diffusion barriers 
formed spontaneously by disulfide bonds enables independent control over the 
release rates of incorporated growth factors, and that in vivo these dressings improve 
several aspects of wound healing in db/db mice.  
 
 
1. Introduction 
Chronic foot ulcerations affect approximately 25% of the diabetic population[1]. 
These wounds are generally painful and lead to a significant decline in quality of life[2]. 
While a variety of options are available to treat these wounds, many are inefficient 
when used in isolation due to a diverse combination of causative factors including 
mechanical stress, chronic inflammation, neuropathy, ischemia, and innate 
biomolecular changes[3]. Because of this complexity, it is often challenging to promote 
full wound resolution, leaving the door open for opportunistic infections that set the 
stage for a downward spiral leading to amputation. 
 In order to increase the overall probability of wound closure and reduce the 
progression to more serious complications, there is a need for efficient strategies to 
address each of the factors that contribute to the formation of a chronic wound. While 
factors such as mechanical stress can be effectively addressed using offloading 
orthotics[3a], methods for addressing other contributing factors including neuropathy, 
ischemia, and chronic inflammation are much less successful. Many times these other 
factors lead to dysregulation of the cell signaling that normally occurs during the 
healing of acute wounds in healthy individuals[3c, 4]. In these healthy wounds, 
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combinations of growth factors and cytokines are released to coordinate the behavior 
of cells involved in the repair process[5]. However, in diabetic individuals these signals 
are commonly disrupted and contribute to the formation of chronic ulcerations[3c, 4]. 
 This disruption in signaling has been a motivating factor for attempting to use 
exogenous growth factors as a means to spur tissue repair[6].  Unfortunately, despite 
many promising candidates only a small fraction of growth factors have been 
successfully translated to clinics around the world. Examples of these include platelet-
derived growth factor BB (PDGF-BB) in the USA and fibroblast growth factor 2 (FGF-
2) in China and Japan. However in the case of PDGF-BB, the currently approved 
formulation carries concerns regarding both the efficacy and safety and has been given 
a ‘black box’ warning by the FDA[7]. 
 The poor efficacy and safety issues of growth factor-based therapeutics likely 
arise in part due to a non-optimal delivery strategy and physiologically inappropriate 
dosings. In the clinic, PDGF-BB is delivered via a carboxymethylcellulose-based gel 
that results in a large bolus release of growth factor upon application. Due to the short 
temporal persistence of PDGF-BB in vivo (intravenous t1/2 = 2 minutes)[8], this method 
of delivery requires a high concentration of growth factor to spur noticeable changes 
in wound healing[9]. Additionally, unlike the endogenous process of wound repair that 
utilizes multiple growth factors[5b, 10], PDGF-BB is delivered as a lone therapeutic, 
eliminating any potential beneficial interactions arising from combination therapies that 
may increase overall effectiveness. 
 In order to enable the use of multiple growth factors and break the need to use 
high concentrations of growth factors, we aimed to establish a new therapeutic 
strategy that possesses several key features: 1) the platform should have the 
potential to be easily integrated into platforms used in a clinical setting and 2) it 
should possess the ability to deliver multiple growth factors and control their delivery 
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kinetics. We use the layer-by-layer (LbL) process to construct drug-loaded multilayer 
films and overcome the limitations of current growth factor-based therapeutics, 
establishing a flexible strategy for developing more effective treatments. LbL is an 
iterative self-assembly process that takes advantage of complimentary interactions 
(e.g. electrostatics, hydrogen bonding) to control the deposition of materials on a 
substrate of interest[11]. It can achieve high therapeutic loadings compared to 
traditional polymer blends, and due to its amenability to water-based solutions, is an 
ideal platform for assembling biomaterials that contain sensitive biologics including 
growth factors[12]. In this study, we use the LbL process to develop a flexible platform 
that allows the delivery of multiple growth factors from commercially available wound 
dressings. We establish the ability to release physiologically relevant amounts of 
active growth factors over approximately two weeks and evaluate the effects of 
combination growth factor therapy in a murine model of diabetic ulcer healing. 
 
2. Results & Discussion 
Woven nylon contact layer dressings were identified as the substrate of choice. 
In the clinic these dressings are generally placed in contact with wounds to act as a 
barrier between the wound tissue and gauze, with the mesh size of the contact layer 
preventing tissue growth into the gauze. Here, we coated these contact dressings via 
LbL to create bioactive dressings incorporating vascular endothelial growth factor 165 
(VEGF) and/or PDGF-BB (Figure 1).  VEGF and PDGF-BB were chosen due to their 
demonstrated efficacy as a pro-angiogenic therapy[13], allowing the evaluation of the 
LbL platform as a viable delivery strategy by targeting the common issue of limited 
angiogenesis in diabetic ulcers. This therapeutic strategy is based on the stimulation 
of vascular sprouting and vessel growth via VEGF signaling, and the subsequent 
stabilization of nascent vasculature by mural cells via PDGF-BB mediated 
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recruitment[14]. While this strategy has been demonstrated in various tissue 
environments in vivo[15], the impact of soluble, controlled-release VEGF/PDGF-BB into 
the bed of a chronic wound has yet to be established; instead, previous work has relied 
on engineered matrix binding proteins for improving efficacy[16]. The chronic wound 
environment carries additional challenges for soluble growth factors compared to 
acutely healing tissues, with chronic environments displaying elevated levels of 
proteases and pro-inflammatory cytokines, as well as varying levels of hypoxia, all 
factors that lead to an aggressive and degradative microenvironment that can reduce 
the effectiveness of growth factors and other protein-based therapeutics[17]. 
Figure 1. Helium ion images of an a) uncoated nylon wound dressing and b) LbL-coated 
wound dressing. Growth factor-eluting films form continuous films that bridge the pores of 
the underlying woven nylon. Scale bars 20m and 50m respectively. 
 
Therapeutic dressings were fabricated using a repeating tetralayer architecture 
that consists of hydrolytically degradable poly(-amino esters) (Poly1 & Poly2)[18], 
poly(acrylic acid) (PAA), VEGF and/or PDGF-BB, and heparan sulfate (HS) (Figure 
2a). The use of Poly1/Poly2 allows for control over the degradation rate of the LbL 
film[19], while PAA and HS have been validated in the past as a method for incorporating 
active growth factors into LbL dressings[20]. In the case of dermal wound healing, 
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dressing changes are likely to occur within one to two weeks. Dressing architectures 
were designed for release kinetics with an exponentially decaying release of VEGF in 
combination with sustained release of PDGF-BB. These kinetics align with previous 
work establishing the optimal temporal kinetics for promoting angiogenesis with 
combination delivery of VEGF and PDGF-BB, and relies on VEGF driving the initial 
formation of new vasculature followed by maturation of the vessels via PDGF-BB-
mediated mural cell recruitment[15a].  In order to achieve this temporal program, PDGF-
BB-containing films were assembled in direct contact with the woven nylon substrate. 
VEGF-containing films were subsequently assembled on top of the PDGF-BB films in 
order to coordinate distinct release via surface-based erosion (Figure 2a). 
 
Figure 2. a) Architecture of initial wound dressing. A PDGF-BB-containing film is deposited 
in contact with the nylon substrate. Subsequently, a VEGF-containing film is deposited on top 
of the PDGF-BB film. (b) Release profiles for VEGF and PDGF-BB for dressing architecture 
in part (a). (c) Architecture of dressing containing dithiol-crosslinked diffusion barriers. 
Periodic cysteine-modified PAA layers within the PDGF-BB section of the dressing reduce 
interfilm diffusion and enable independent control of release kinetics. (d) Release profiles for 
VEGF and PDGF-BB from dressing architecture shown in part (c).  *, p<0.05; **, p<0.01 vs 
PDGF-BB release percent. 
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The in vitro release profile for the VEGF/PDGF-BB dressing is shown in Figure 
2b and reveals that significant interlayer diffusion occurs during the construction of the 
LbL film[21], resulting in a polymer blend that lacks distinct release kinetics for each 
growth factor. In order to reduce the propensity for interlayer blending, selectively 
crosslinked “barrier layers” were added to the design. This was carried out through 
chemical conjugation of cysteine to PAA (PAAC) using well-established EDC chemistry 
(average cysteine:COOH ; 1:4) in order to enable reversible crosslinking via formation 
of disulfide bonds. Second generation dressings were fabricated with a PAAC layer 
replacing PAA in every third tetralayer of the PDGF-BB section of the film and a barrier 
region of higher crosslinking between the PDGF-BB and VEGF sections of the film 
(Figure 2c). Previous studies using neutron reflectivity have shown that this spacing is 
sufficient to prevent blending and interaction of two distinct LbL layers[22]. Here, this 
periodic spacing promotes intra-layer crosslinking of the PAAC within the individually 
deposited layer instead of crosslinking between the different PAAC layers of the PDGF-
BB section of the film, This sets up diffusion barriers that reduce the level of film 
blending but do not completely inhibit PDGF-BB release.  
The PAAC-containing dressings were subsequently characterized to determine 
the impact of the barrier layers on the release behavior of VEGF and PDGF-BB. As 
shown in Figure 2d, the release from the top layers containing VEGF with PAA and HS 
is not impacted. In contrast, the kinetics of PDGF-BB release are significantly altered, 
with release now sustained for approximately 11 days (Figure 2d), leading to significant 
differences in release behavior. However, the total protein loading is not affected by 
the incorporation of PAAC (Table 1). In order to verify that the delayed release 
behavior of PDGF-BB is occurring due to the formation of intra-layer disulfide bonds, 
dressings were fabricated with PAA-C replacing PAA for all layers throughout the 
dressings (Figure S1). In these dressings, minimal protein release is observed due to 
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extensive crosslinks formed throughout the thickness of the film (between each 
individually deposited PAAC layer). The system with staggered VEGF/PDGF-BB 
release profile represents the more optimal release kinetics as discussed above, and 
was selected for further study. 
Dressing 
Architecture 
Total VEGF 
Release at Day 14 
Total PDGF 
Release at Day 14 
PAA 238±50.5 ng/cm2 170.3±59.9 ng/cm2 
PAA + Periodic PAAC 338.4±76.7 ng/cm2 156.9±53.1 ng/cm2 
PAAC 21.6±14.6 ng/cm2 10.7±3.5 ng/cm2 
Table 1. Total protein release from various dressing architectures. Total release from dressings 
with only PAA and those containing periodic PAAC are not statistically different, whereas 
dressings with only PAAC have minimal protein release out to 14 days (italics: p<0.05 vs. PAA 
& PAA+PAAC).  
 
While it has been previously demonstrated that growth factors incorporated into 
LbL films remain active[12g, 20], the introduction of free thiols throughout the PDGF-BB 
section of the film raises concerns regarding thiol-mediated denaturation of the 
encapsulated PDGF-BB. In order to verify that active PDGF-BB is being released, two 
in vitro assays were performed. First, PDGF-BB released during the first 24 hours of 
degradation was added to cultures of primary human dermal fibroblasts (HDF) from 
hyperglycemic patients, followed by measurement of PDGF Receptor  (PDGF-R) 
phosphorylation. Significant phosphorylation was observed in cells stimulated with 
release solutions (33.2±14.9 ng/mL pPDGF-R), while no detectable phosphorylation 
was found for PBS-stimulated cells. This data verifies that PDGF-BB released from 
dithiol-crosslinked films retains the ability to phosphorylate cognizant receptors. The 
second verification of PDGF-BB activity was provided in a migration assay of HDF. 
Degradation solutions from 12 hrs, 6.6 days, and 10.8 days were added to HDFs and 
the migration compared to PBS controls. In all cases, degradation solutions promoted 
increases in cell migration over PBS controls, and no significant difference was 
observed between the different degradation time points, indicating that following 
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dressing fabrication, no functional protein degradation occurs within the dressings over 
the timeframe of release of approximately 11 days (Figure 3 and Figure S2 for 
example migration images). 
 
Figure 3. Growth factors over the course of 11 days promote migration of human dermal 
fibroblasts. *, p<0.05; **, p<0.005. n=7-10. 
 
Having confirmed that the dithiol-crosslinked films retain the ability to release 
active proteins, we next aimed to understand how the dressing impacts the process of 
wound repair. Owing to the fact that tissue repair is a complex biological process that 
is poorly recapitulated in an in vitro setting, a majority of characterization focused on 
the in vivo impact in db/db mice. db/db mice are a genetic model of type II diabetes, 
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and are commonly used to explore therapeutic strategies for healing diabetic ulcers[23].  
In this study, two full thickness skin wounds  (through the panniculus carnosus) were 
made on the backs of mice. Wounds were covered with either control dressings (bare 
nylon substrate), dressings containing both VEGF and PDGF-BB (average VEGF 
dose: 93±25 ng; average PDGF-BB dose: 43±15ng), or dressings containing either 
VEGF or PDGF-BB that possess the same individual release kinetics and dosage level 
as found in the combination dressing (Figure 2d and Figure S3). A transparent 
adhesive dressing was then applied over the wound to hold the therapeutic dressing 
in place and prevent infection. 
Wound evaluation at Day 7 and Day 14 reveals significant qualitative and 
quantitative differences between the treatment regimens. Gross examination of the 
wounds shows overall changes to the visual appearance of the wounds (Figure 4). 
Control wounds and those treated with only VEGF tend to appear overall lighter in color 
than PDGF-BB and combination dressings one week after surgery. In the latter cases, 
the deeper red granulation tissue appears to align with the characteristics of wound 
that is healing properly; the deeper red color is likely due to a higher density of blood 
vessels, and is characteristic of healthy, vascularized tissue[24]. Quantifying the extent 
of vessel growth via immunofluorescence labeling of CD31 indicates a significant 
increase in vascular density in the VEGF/PDGF-BB combination treated wounds 
compared to control wounds and those treated with only VEGF (Figure 5), along with 
the combination treatment leading to the highest maximum density of vessels in the 
wound tissue that we observed at week one. The staining of -smooth muscle actin 
shows limited maturation of the vessels by mural cells at week one, although there is 
evidence of the maturation process beginning in the wounds undergoing the 
combination treatment.  By two weeks after surgery the wounds treated with any of the 
growth factor therapies exhibit an increase in angiogenesis compared to the untreated 
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control wounds. However, the combination treatment has the highest average vessel 
density and a maximum vessel density approximately twice that of any other treatment, 
in agreement with previous work demonstrating the benefit of the VEGF/PDGF-BB 
treatment. These combination-treated wounds also display a high number of mural 
cells surrounding the vessels, indicating that a robust, mature vascular system is being 
generated.  
 
Figure 4. Representative wound images of visual appearance at day 7 and day 14 for each 
treatment regimine. 
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Figure 5. (a) Immunofluorescence images of vessel growth for each treatment regime. Green: 
CD31; Red: -smooth muscle actin; Blue: DAPI. Scale bar 50m (b) Quantification of vessel 
density at day 7. (c) Quantification of vessel density at day 14. *, p<0.01 vs. control; **, 
p<0.001 vs. control; #, p<0.05 vs. VEGF. 
 
Having established that the combination therapy conveys the largest 
improvement in vascularization within the wound bed, we next aimed to establish how 
the different therapeutic strategies affect various processes specific to wound healing. 
One such process is the formation of granulation tissue within the wound[25]. This 
temporary tissue is critical for establishing a matrix that enables reepithilialization, 
helps reduce infection, and provides a means for healing via secondary and tertiary 
intention (two methods of wound healing that involve the formation of significant 
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quantities of granulation tissue to heal the wound). In prior research, PDGF-BB has 
been shown to spur the growth of granulation tissue, however the authors of that work 
used greater than 300 times the amount of PDGF-BB contained in the dressings used 
here[26]. Adding to this information is the fact that PDGF-BB has been shown to 
possess a strong dose-dependent efficacy[9], making it unclear as to how effective the 
bioactive dressings would be at promoting the growth of granulation tissue. It should 
be noted, though, that engineering proteins to increase their matrix retention lifetimes 
have demonstrated efficiency at lower levels of protein[16], suggesting that the 
controlled release strategy used here may be a promising approach. 
To quantify the amount of granulation tissue within each wound, serial tissue 
sections were taken every 250-500um through the entirety of the wounds. The average 
thickness of granulation tissue for each tissue section was measured and the average 
thickness across the wounds determined. At one week, the combination dressings are 
the only treatment to display on average a significant increase in granulation tissue 
over the control wounds (Figure 6). This trend continues at week two, with only the 
combination dressing differentiating itself from control treated wounds. At this point, 
the average thickness of the granulation tissue in the mice undergoing the combination 
treatment is equivalent to the average skin thickness (0.59±0.09mm), meaning this 
new temporary tissue completely fills the wound site. Wounds treated with only PDGF-
BB do not display an increase in granulation tissue; these results demonstrate that the 
strategy of combining growth factors that generate cooperative benefits may be a 
viable strategy for improving both the translational effectiveness of growth factors while 
simultaneously reducing the required dosage levels. Here, the interaction that gives 
rise to formation of additional granulation tissue is likely the higher level of 
angiogenesis in the combination treated wounds. Previous studies have shown that 
expression of dominant-negative VEGF Receptor-2 in the wounds of mice results in 
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lower levels of wound angiogenesis and reduced amounts of granulation tissue[27]. 
Furthermore, poorly vascularized wounds in the clinic are commonly found to be poor 
healers[27-28]. Taken together, these results suggest that the increased growth and 
stabilization of new vessels within the granulation tissue due to beneficial interactions 
of VEGF and PDGF-BB signaling supports an overall increase in amount of granulation 
tissue at day 7 and 14.  
 
Figure 6. (a) Representative histology sections (H&E stain). GT: Granulation Tissue; W: 
Wound Gap; PC: Panniculus Carnosus Gap.  Average thickness of granulation tissue within 
wound bed at (b) day 7 and (c) day 14. *, p< 0.05 vs. control. #, p<0.05 vs. VEGF. 
 
Combining the findings from both the angiogenesis and granulation tissue 
measurements, it is highly likely that differing levels of cellular proliferation exist within 
the wound bed. Immunohistochemistry examination of the fraction of Ki-67 expressing 
cells within the granulation tissue confirms that combination VEGF/PDGF-BB therapy 
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leads to an overall higher fraction of proliferating cells than the other treatment groups, 
with 31.2±4.8% of cells positive for Ki-67 compared to 22.4±2.9%, 20.5±4.9%, and 
9.6±7.3% for VEGF only treatment, PDGF-BB only treatment, and untreated controls, 
respectively (Figure 7). Taking this data together with the angiogenesis and 
granulation tissue measurements indicate that the benefits of combination therapy with 
VEGF with PDGF-BB include enhancing the overall degree of cellular proliferation in 
the wound bed over PDGF-BB used in isolation. 
 
Figure 7. Cellular proliferation in granulation tissue at day 7 and day 14. (a) Representative 
Ki-67 immunohistochemistry sections for each treatment regime at days 7 and 14. Fraction of 
proliferating cells in granulation tissue at (b) day 7 and (c) day 14. *, p<0.05 vs. control; ***, 
p<0.0001 vs. control; ^, p<0.05 vs. PDGF-BB; #, P<0.05 vs VEGF. 
 
In order to gain more insight into the granulation tissue that forms following each 
treatment regime, a rough estimate of the ratio of thick to thin collagen fiber deposition 
was determined via picrosirius red staining. Picrosirius red stain enhances the natural 
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birefringence of fibrillar collagen, allowing easy quantification under cross-polarized 
light[29]. The color undergoes a shift from green to yellow-orange as collagen fibrils 
increase in thickness, allowing differentiation between thin and thick collagen fibers 
(Figure S4). The thick fiber category generally consists of collagen I fibers, while the 
thin fiber category contains the collagen III signal, immature collagen I fibers, and 
collagen I fibers altered during histological processing. Here the ratio of thick to thin 
fibers within the granulation tissue does not vary significantly between treatment 
groups, signifying that at a given time after treatment the collagen within the tissue is 
similar (Table 2). Furthermore, as the wounds heal, the thick to thin ratio increases; 
this trend is in good agreement with the previous observations of the collagen fiber 
ratio in healing wounds[30], indicating that the growth factors used here do not cause 
dramatic alterations in the distribution of collagen within the granulation tissue. This is 
not unexpected as the ratios of collagen types are closely linked with the levels of 
proteases within the tissue microenvironment, and none of the growth factors used 
here are anticipated to shift these levels towards a substantially different proteolytic 
microenvironment.  
Dressing 
Architecture 
Collagen Fiber 
Thick/Thin Ratio 
at Day 7 
Collagen Fiber 
Thick/Thin Ratio 
at Day 14 
Control 4.8±3.8 13.2 ±2.8 
VEGF Only 3.7±1.3 12.3±0.8 
PDGF-BB Only 7.2±2.3 9.3±2.0 
VEGF & PDGF-BB 3.0±0.6 11.9±6.6 
Table 2. Ratio of thick to thin collagen at days 7 and 14. 
One function of this newly formed granulation tissue is to promote wound 
closure, both through myofibroblast-mediated contraction and providing a substrate for 
reepithilialization[25]. The amount of wound contraction was determined by measuring 
the closure of the panniculus carnosus muscle, which is cut through during full-
thickness skin wounding and does not regenerate over the course of the study, while 
the overall rate of closure was determined by the remaining defect in the epidermis. In 
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each case, areal measurements from serial wound sections are used to determine the 
degree of healing. At one week, wounds treated with the combination dressings display 
an increased rate of wound contraction, although this difference disappears by week 
two (Figure 8a,b). The exact mechanism behind the increased contraction at week 
one is currently unknown and under further investigation. The standard mechanism of 
myofibroblast-mediated contraction is a possibility, although the amount of granulation 
tissue present at this time point is not thought to be sufficient to drive contraction. 
 
Figure 8. Closure of the panniculus carnosus at (a) day 7 and (b) day 14. (c,d) Overall wound 
closure at day 7 and 14, respectively. *, p<0.05 vs. control. 
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The overall rate of wound closure, measured by the size of the remaining 
defect in the epidermis, shows no difference between the treatments at one or two 
weeks post wounding (Figure 8c,d). This result is not unexpected, since neither 
VEGF nor PDGF-BB are motogenic towards keratinocytes but instead expressed by 
keratinocytes as paracrine signals for cells in the underlying granulation tissue[5b, 31]. 
While VEGF has been shown to increase the rate of wound closure in other 
experiments[32], those results use significantly more growth factor than used here. In 
that case VEGF is suggested to increase the recruitment of bone marrow-derived 
cells and alter expression of various growth factors including PDGF and FGF2. Here, 
we do not find indications of sufficient modulation of these growth factor networks to 
increase the rate of wound closure. Increasing the dosage of PDGF-BB is not likely to 
alter this finding, as significantly higher doses of PDGF-BB have been found to 
simply promote the formation of granulation tissue and not drive reepithilialization[26]. 
Furthermore, increasing the dosage of VEGF is likely not a translatable strategy, as 
large doses of VEGF promote vascular permeability, bleeding, and the subsequent 
formation of disordered vasculature[33]. Instead, the addition of the mesenchymally 
derived growth factor fibroblast growth factor-7 (FGF-7) may stimulate the migration 
of epidermal keratinocytes over the newly formed granulation tissue[31]. In addition, 
hepatocyte growth factor (HGF) may be an interesting target for increasing the rate of 
epithelialization, as c-met signaling has been shown to play an important role in 
keratinocyte migration[34]. In either case, the flexibility of this LbL dressing allows for 
easy adaptation to include these additional bioactive factors that, in conjunction with 
the VEGF/PDGF-BB therapy, may provide a comprehensive combinatorial strategy 
that drives the multifaceted process of wound repair. 
 
3. Conclusion 
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Bioactive dressings assembled using the LbL process provide a means for 
controlling the delivery of multiple active growth factors that are implicated in the 
process of wound repair. These dressings dramatically reduce the amount of growth 
factor necessary for improved functional outcomes and do not require the use of 
modified proteins, laying the foundation for both an exploratory platform for 
investigative research and a translational modality for potential therapeutic strategies. 
As a proof of concept, combination dressings containing VEGF and PDGF-BB were 
fabricated and evaluated using a murine model of chronic wound healing. In addition 
to promoting angiogenesis, this combination of growth factors also promotes 
significant increases in the formation of granulation tissue and/or cellular proliferation 
when compared to dressings utilizing single growth factor therapeutics. More broadly, 
the dressings used here achieve these results at protein levels between 300 and 700 
times lower than traditional delivery methods, and at comparable protein levels to the 
newest strategies involving designer protein constructs[16,26]. 
 
 
4. Experimental Section 
4.1 Materials 
 Polyacrylic acid (Mw≈1,000,000) was obtained from Polysciences, Inc. 
(Warrington, PA). Poly (-amino ester) 1 and 2 (Poly1 and Poly2) were synthesized as 
previously described[18]. Heparan sulfate (Mw≈14.6 kDa) was obtained from Celsus 
Laboratories, Inc. (Cincinnati, OH). 5,5’-Dithiobis(2-nitrobenzoic acid) (Ellman’s 
Reagent, BioReagent) and L-Cysteine (BioUltra) were obtained from Sigma-Aldrich (St. 
Louis, MO). Sulfo-NHS and EDC were obtained from Thermo Fisher Scientific 
(Waltham, MA). Sodium acetate buffer (3 M) was obtained from Sigma Aldrich. Carrier-
free PDGF-BB and VEGF-165 were obtained from BioLegend, Inc. (San Diego, CA). 
PDGF-BB and VEGF-165 Duoset ELISA kits and phospho-PDGF-R ELISA kits were 
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obtained from R&D Systems (Minneapolis, MN). Oris cell migration assays were 
obtained from Platypus Technologies (Madison, WI). Tegaderm woven nylon wound 
dressings and adhesive dressings were obtained from 3M (Minneapolis, MN). Rat anti-
mouse CD31 antibody (MEC 13.3 clone, 553370) was obtained from BD Biosciences 
(San Jose, CA). Goat anti-mouse -smooth muscle actin antibody (PA5-18292) was 
obtained from Thermo Fisher Scientific Inc. Chicken anti-rat Alexa488 (A21470) and 
chicken anti-goat Alexa594 (A21468) were obtained from Life Technologies. Rabbit 
anti-mouse Ki-67 (ab16667) was obtained from Abcam (Cambridge, MA). Chicken 
serum (16110-082) was obtained from Life Technologies. Proteinase K (17916) was 
obtained from Thermo Fisher Scientific Inc. DAPI and Prolog Gold antifade reagent 
were obtained from Life Technologies.  Primary human dermal fibroblasts were a gift 
from Dr. Aristidis Veves (Joslin-Beth Israel Deaconess Foot Center). db/db mice were 
obtained from The Jackson Laboratory (strain: BKS.Cg-Dock 7m +/+ Leprdb/J). 
 
4.2 PAA-Cysteine Conjugation 
 Briefly, EDC and Sulfo-NHS were added at a ratio of 1:2 to a 3g/L PAA solution 
in 0.5 M NaCl and allowed to react for 25 minutes at pH 6.0. 2-mercaptoethanol was 
then added and the pH adjusted 7.0. L-cysteine was then added to a final concentration 
of 3g/L and allowed to react for 3 hours. The resulting solution was subsequently 
dialyzed in decreasing concentrations of acidic NaCl over the course of 3 weeks using 
dialysis tubing with a MWCO=50,000. The resulting solution was lyophilized to obtain 
the purified PAAC. Ellman’s reagent was then used to determine the degree of PAA 
conjugation following reduction of disulfide bonds in the PAAC using tris-(2-
carboxyethyl)phosphine.  
 
4.3. Preparation of Polyelectrolyte Dipping Solutions 
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 Linear poly(ethlyeneimine) (LPEI) solutions were prepared as 10mM solutions 
using deionized water, pH 4.25. Polystyrene sulphonate (PSS) solutions were 
prepared as 10mM solutions using deionized water, pH 4.75. Poly1, Poly2, heparan 
sulfate, PAA, and PAA-C dipping solutions were prepared as 2mg/mL solutions in 
100mM sodium acetate buffer, pH 5.0, 0.2 m filtered. PDGF-BB and VEGF dipping 
solutions were prepared as 50g/3mL solutions in 100mM sodium acetate buffer, pH 
5.0, 0.2 m filtered. All wash baths were 100mM sodium acetate, pH 5.0 except for use 
with LPEI and PSS, which were washed with DI water at a pH corresponding to the 
respective dipping solution. 
 
4.4. Film Construction 
 Woven nylon dressings were precut with a 6mm diameter biopsy punch prior to 
dipping. Dressings were attached to a custom dipping arm for a Carl Zeiss HMS 
programmable slide stainer and oxygen plasma treated for 5 minutes in pure oxygen. 
Immediately following plasma treatment, ten LPEI/PSS bilayers were deposited to form 
a nondegradable baselayer of uniform charge using a dipping cycle of 5 minutes per 
polymer solution followed by two one minute washes in DI water. Following the 
baselayer coating process, dressings were dipped using a repeating tetralayer 
architecture of Poly1 or Poly 2, PAA or PAA-C, PDGF-BB or VEGF, and heparan 
sulfate (Figure 2).  All polymer solutions were dipped for 5 minutes followed by two 
washes of one minute each. Growth factor solutions were dipped for 10 minutes 
followed by a single wash step of 10 seconds. PDGF-BB containing film was deposited 
following the baselayer step, with VEGF containing film subsequently deposited on top 
of the PDGF-BB film. In dressings that contained only one growth factor, the other 
growth factor was replaced with either Poly1 or Poly2 depending on which Poly was 
  
22 
 
being used in that tetralayer. All solutions were changed when a new section of the 
films were started (e.g. PDGF-BB section, VEGF section). Each section of the films 
(VEGF or PDGF-BB) contained 40 tetralayer repeats, while the highly crosslinked 
barrier between VEGF and PDGF-BB sections in the PAAC dressings contained 5 
bilayer repeats of PAAC and Poly2.  
 
4.5 In Vitro Release Profiles and Growth Factor Loading 
 Film-coated dressings were placed in sterile microcentrifuge tubes containing 1 
mL of sterile PBS and carried out at 37°C. At each timepoint, dressings were removed 
from their current tubes and placed into new microcentrifuge tubes. The release 
solutions were aliquoted and frozen. Degradations were carried out over the course of 
two weeks. Degradation solutions were subsequently characterized via ELISA to 
determine the average release profiles and total growth factor loading. Each timepoint 
was measured in duplicate and at least 3 different dressings were used to determine 
the release profiles and average growth factor loadings. 
 
 4.6 Growth Factor Activity Assays 
HDFs were cultured in DMEM with 5% FBS, 1% antibiotic-antimycotic, and 2 
mM L-glutamine. PDGF-R phosphorylation ELISA and cell migration assays were 
carried out according to the manufacturers instructions. Briefly, for the phosphorylation 
assays cells were grown to 80% confluence and serum starved for 8 hours. Dressing 
degradation solution or PBS was added to the cultures to a final PDGF-BB 
concentration of 5ng/mL. Stimulation was allowed to occur for 15 minutes, followed by 
washing and cell lysis. Lysates were then analyzed via ELISA. For the cell migration 
assays, HDFs were seeded in the Oris cell migration plate and cultured for 12 hours. 
Stoppers were removed and cells washed. Serum-free media with either release 
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solutions from various timepoints or PBS was added to the cells and incubated for 12 
hours. PDGF-BB concentration was normalized to 420pg/mL for each timepoint. Cells 
were then fixed, stained with DAPI, and the extent of cell migration measured. 
 
4.7 In Vivo Dressing Evaluation 
 All animal work was performed in accordance with protocols approved by the 
Committee on Animal Care at the Massachusetts Institute of Technology. Female 
db/db mice were obtained at 8 weeks of age and were 10-12 weeks old at the time of 
surgery. Daily blood glucose measurements were used to confirm the onset of diabetes, 
which was defined as 10 continuous days with blood glucose levels above 300mg/dL. 
Three to five days prior to surgery, hair on the dorsum of db/db mice was removed 
using a depilatory cream. Immediately prior to surgery, mice were anesthetized with 1-
3% isofluorane and given 0.1 mg/kg analgesics (Buprenex). The skin was prepared 
with chlorhexidine and two 6mm full-thickness skin wounds were made off mid-line 
using biopsy punches. Coated dressings or bare control dressings were placed directly 
on the wounds. Coated dressings were fabricated immediately prior to surgery, with 
no sterilization protocols used following fabrication due to skin wounds being non-
sterile. The therapeutic dose was chosen to be inline with other recent reports[16].  The 
wounds were then covered with adhesive Tegaderm to hold the dressings in place and 
reduce the chance of infection. Body weights were measured daily to ensure no mice 
were included in analysis that lost greater than 10% of their body weight following 
surgery. Wounds displaying overt signs of infection were also excluded from the study. 
One and two weeks after surgery, mice were euthanized and the wound tissues taken 
for histological analysis. For all animal experiments, final group sizes were n=5-8. 
 
4.8 Histology 
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 Wound tissue was fixed in formalin-free zinc fixative for 48 hours. The wounds 
were subsequently embedded in paraffin and serial sections taken every 250m 
through the entirety of the wound. H&E staining was done at each level and used to 
make 2-D reconstructions of the wound. Wound size and panniculus carnosus gap 
were measured using area measurements from these 2-D reconstructions. Granulation 
tissue area was manually isolated and measured for each section and the average 
area across the wound determined. Unstained slides were taken at each level for 
immunohistochemistry (IHC) and picrosirius staining. IHC staining of CD31 and -SMA 
were carried out with primary antibody concentrations of 1:100 and 1:200, respectively. 
Secondary antibody staining was done at a concentration of 1:500. Ki67 staining was 
done at an antibody concentration of 1:100. All measurements were carried out using 
ImageJ.  
 
4.9 Statistics 
 For normally distributed data sets with equal variances, one-way ANOVA testing 
followed by a Tukey post-hoc test was carried out across groups. For normal data sets 
with unequal variances, a Welch test was performed followed by Games-Howell post-
hoc testing. In cases that required non-parametric evaluation, a Kruskal-Wallis ANOVA 
was carried out and followed by Steel-Dwass post-hoc testing. In all cases, significance 
was defined as p≤0.05. Outliers were identified using the outlier labeling rule with k=2.4. 
A Grubbs outlier test with =0.01 was then used on identified outlier candidates to 
confirm outliers for exclusion. For all animal experiments, each group n=5-8. Statistical 
analysis was carried out using SPSS, JMP, and Excel.  
 
 
Supporting Information  
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Supporting Information is available from the Wiley Online Library or from the author. 
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